Literature DB >> 11003620

Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.

T Shimonishi1, K Isse, F Shibata, I Aburatani, K Tsuneyama, H Sabit, K Harada, K Miyazaki, Y Nakanuma.   

Abstract

We examined immunohistochemically the possible participation of the Fas/Fas ligand (FasL) system in intrahepatic cholangiocarcinoma (ICC) during the escape from immune surveillance, using 68 cases of ICC, 29 cases of normal intrahepatic large bile ducts, and 18 cases of biliary dysplasia. Apoptosis of tumor-infiltrating lymphocytes (TIL) was examined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Fas was weakly expressed in normal intrahepatic bile ducts. Almost all biliary dysplasia and well-differentiated ICCs showed moderate to marked expression of Fas, while Fas expression was variable in moderately and poorly differentiated ICCs. Down-regulation of Fas expression was significantly correlated with histologic de-differentiation, vascular invasion, the size of ICCs, and short survival of ICC patients. By in situ hybridization, FasL mRNA were frequently and strongly expressed in biliary dysplasia compared with non-neoplastic intrahepatic bile duct. In well-differentiated ICCs, FasL mRNA expression was frequent and intense. But, the expression gradually decreased in moderately and poorly differentiated ICCs. Down-regulation of FasL mRNA expression in ICCs was correlated with perineural invasion and tumor size (over 4 cm) (P <.05). Apoptotic TIL were more frequent in ICC foci than in non-neoplastic foci remote from ICC foci. These findings suggest that a tumor evasion mechanism involving Fas/FasL exists in ICC; frequent and intense expression of FasL mRNA in well-differentiated ICCs enable them to escape immune surveillance by counterattacking Fas-bearing TIL. This counterattack becomes insensitive in poorly differentiated ICCs, in which the down-regulation of Fas gives them a resistance against the FasL-expressing TIL. These mechanisms may be involved in the tumor progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11003620     DOI: 10.1053/jhep.2000.18192

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

1.  Polymorphisms of the FAS and FASL genes and risk of breast cancer.

Authors:  Wenmin Wang; Zhongqiu Zheng; Wenjie Yu; Hui Lin; Binbin Cui; Feilin Cao
Journal:  Oncol Lett       Date:  2011-12-28       Impact factor: 2.967

2.  Conformation and free energy analyses of the complex of calcium-bound calmodulin and the Fas death domain.

Authors:  Jonathan D Suever; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Biophys J       Date:  2008-09-26       Impact factor: 4.033

3.  Trifluoperazine regulation of calmodulin binding to Fas: a computational study.

Authors:  Di Pan; Qi Yan; Yabing Chen; Jay M McDonald; Yuhua Song
Journal:  Proteins       Date:  2011-06-07

Review 4.  Immunotherapy in gastrointestinal cancers.

Authors:  Patrick Grierson; Kian-Huat Lim; Manik Amin
Journal:  J Gastrointest Oncol       Date:  2017-06

5.  Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients.

Authors:  Adel Mohammadzadeh; Ali Akbar Pourfathollah; Mohammad Taher Tahoori; Saeed Daneshmandi; Ladan Langroudi; Masoumeh Akhlaghi
Journal:  Rheumatol Int       Date:  2011-08-31       Impact factor: 2.631

6.  Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).

Authors:  Selwyn M Vickers; Nirag C Jhala; Eun-Young Ahn; Jay M McDonald; George Pan; Kirby I Bland
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

7.  Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas.

Authors:  Z Y Li; S Q Zou
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

8.  Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand.

Authors:  Elizabeth H Humphreys; Kevin T Williams; David H Adams; Simon C Afford
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

9.  Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells.

Authors:  Hee-Jung Yoo; Bo-Ra Yun; Jung-Hee Kwon; Hyuk-Soo Ahn; Min-A Seol; Mi-Jin Lee; Goung-Ran Yu; Hee-Chul Yu; BeeHak Hong; KwanYong Choi; Dae-Ghon Kim
Journal:  Exp Mol Med       Date:  2009-02-28       Impact factor: 8.718

10.  Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma.

Authors:  Enrique Lerma; Marisa Romero; Alberto Gallardo; Cristina Pons; Josefina Muñoz; Josefina Fuentes; Belen Lloveras; Lluis Catasus; Jaime Prat
Journal:  Virchows Arch       Date:  2007-11-14       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.